Clinical

Dataset Information

0

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)


ABSTRACT: The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2315052 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2386782 | ecrin-mdr-crc
| 2366035 | ecrin-mdr-crc
2018-11-21 | GSE110785 | GEO
| 60837 | ecrin-mdr-crc
| 2352790 | ecrin-mdr-crc
| 2383608 | ecrin-mdr-crc
| 2401722 | ecrin-mdr-crc
| 2392221 | ecrin-mdr-crc
| 108311 | ecrin-mdr-crc
| S-EPMC8658167 | biostudies-literature